Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.

Acta psychiatrica Scandinavica - 1 Jan 2019

Na Takuathung M, Hanprasertpong N, Teekachunhatean S, Koonrungsesomboon N

Abstract excerpt

OBJECTIVE: To determine the impact of CYP1A2 genetic polymorphisms on the pharmacokinetics of CYP1A2-metabolized antipsychotic drugs in humans by means of systematic review and meta-analysis. METHOD: A systematic search was conducted in PubMed and Scopus databases as of June 26, 2018. Studies reporting the pharmacokinetic parameters of CYP1A2-metabolized antipsychotic drugs in individuals who were genotyped for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clozapine

Share to Cytochrome P-450 CYP1A2

Share to Ethnicity

Share to Haloperidol

Share to Olanzapine

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 30112761
DOI: 10.1111/acps.12947

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.PMID 30112761Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Semantic proximity Read ↗

Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogeneticsSemantic proximity Read ↗

Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Pharmacogenetics of second-generation antipsychotics.Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an updateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.